https://practicaldermatology.com/news/candin-meets-primary-endpoint-in-phase-3-common-wart-trial/2487261/
CANDIN Meets Primary Endpoint in Phase 3 Common Wart Trial - PracticalDermatology
Nielsen BioSciences announced positive topline findings from its Phase 3 trial evaluating CANDIN (Purified Candida albicans Antigen) for the treatment of …
primary endpointcommon wartcandinmeetsphase